Russian Journal of Organic Chemistry, Vol. 40, No. 6, 2004, pp. 902–907. Translated from Zhurnal Organicheskoi Khimii, Vol. 40, No. 6, 2004, pp. 938–943. Original Russian Text Copyright © 2004 by Pryadeina, Burgart, Saloutin, Kodess, Ulomskii, Rusinov.

> Dedicated to Full Member of the Russian Academy of Sciences O.N. Chupakhin on his 70th Anniversary

Synthesis of 7-Alkyl(aryl)-6-alkoxycarbonyl-5-fluoroalkyl-1,2,4-tri(tetr)azolo[1,5-*a*]pyrimidines

M. V. Pryadeina¹, Ya. V. Burgart¹, V. I. Saloutin¹, M. I. Kodess¹, E. N. Ulomskii², and V. L. Rusinov²

¹ Postovskii Institute of Organic Synthesis, Ural Division, Russian Academy of Sciences, ul. S. Kovalevskoi 22/20, Yekaterinburg, 620219 Russia e-mail: saloutin@ios.uran.ru

² Ural State Technical University, Yekaterinburg, 620002 Russia


Received January 10, 2004

Abstract—Fluorinated 3-oxo esters react with aldehydes and 3-amino-1,2,4-triazoles and 5-aminotetrazoles to give, respectively, 7-alkyl(aryl)-6-alkoxycarbonyl-5-fluoroalkyl-1,2,4-triazolo[1,5-*a*]pyrimidines and -tetrazolo[1,5-*a*]pyrimidines. The same heterocyclic products can be obtained by reaction of 2-benzylidene-2-fluoroacyl esters with the corresponding aminoazoles.

1,2,3,4-Tetrahydropyrimidin-2-one derivatives attract interest as potential biologically active compounds. Specifically, some 1,2,3,4-tetrahydropyrimidin-2-ones which are isosteric to known drugs of the Nifedipine series were shown to exhibit a strong antihypertensive effect [1]. Tetrahydropyrimidin-2-ones can be prepared by Biginelli's three-component condensation of 3-oxo esters, aldehydes, and urea derivatives [2] or via Etwal's modification through 2-arylmethylene-3-oxo esters [3]. Fluoroalkyl-containing 1,3-dicarbonyl compounds react with benzaldehyde and urea (or thiourea) to afford hexahydropyrimidin-2-ones [4, 5] instead of the expected tetrahydropyrimidin-2-ones. We have found no published data on reactions of aminoazoles with aldehydes and fluorinated 3-oxo esters, while nonfluorinated analogs are widely used for the synthesis of fused azolopyrimidines [6-9].

In the present work we studied synthetic routes to tri- and tetrazolo[1,5-*a*]pyrimidines on the basis of fluoroalkyl-containing 3-oxo esters and their derivatives according to Biginelli's reaction. We have found that reactions of fluoroalkyl-containing 3-oxo esters **Ia** and **Ib** with aldehydes and 3-amino-1,2,4-triazole (**IIIa**) or 5-aminotetrazole (**IIIb**) lead to formation of the corresponding tri- and tetrazolopyrimidines **IVa**– **IVc**, **V**, **VIa**, **VIb**, and **VIIa–VIIc** (Scheme 1). As aldehyde component we used benzaldehyde, *p*-methoxybenzaldehyde, and acetaldehyde. Heterocycles **VIa, VIb, VIIa**, and **VIIb** were also synthesized by cyclocondensation of 2-benzylidene-2-fluoroacyl esters **IIa** and **IIb** with aminoazoles **IIIa** and **IIIb**; in these cases, the yields were greater. Lower yields of the target products in the three-component condensation are explained by greater contribution of various side processes. For example, we isolated *N*-benzylideneamino derivatives **VIIIa** and **VIIIb** as by-products which were formed by condensation of aldehydes with aminoazoles.

Unlike transformations of fluorinated 1,3-dicarbonyl compounds in reactions with urea and thiourea [4, 5], the major products isolated in the reactions of 3-oxo esters **Ia** and **Ib** with aminoazoles **IIIa** and **IIIb** were substituted dihydrotri- and -tetrazolopyrimidines **VIa**, **VIb**, and **VIIa–VIIc**. However, in some cases we succeeded in obtaining tetrahydroazolopyrimidines **IVa** and **IVb** which contained a hydroxy group in the geminal position with respect to the fluorinated substituent. Tetrahydroazolopyrimidines **IVc** and **V** were the only products isolated in the condensation of 3-oxo ester **Ia** with acetaldehyde and amines **IIIa** and **IIIb**. Heating of compounds **IVa** and **IVb** in boiling toluene in the presence of *p*-toluenesulfonic acid with removal of the liberated water by azeotropic




Ia, IIa, IVa–IVc, V, VIa, VIa^{*}, VIIa, VIIc, $R_F = CF_3$, R = Et; Ib, IIb, VIb, VIIb, $R_F = H(CF_{2/2}, R = Me$; IVa, VIa, VIa^{*}, VIb, VIIa, VIb, R' = Ph; IVc, V, R' = Me; IVb, VIIc, R' = 4-MeOC₆H₄; IIIa, V, VIa, VIa^{*}, VIb, VIIIa, X = CH; IIIb, IVa–IVc, VIIa–VIIc, VIIIb, X = N.

distillation afforded dihydrotetrazolopyrimidines **VIIa** and **VIIc**.

Theoretically, the above cyclocondensations with 5-aminotetrazole could lead to formation of two regioisomeric heterocyclic products \mathbf{A} and \mathbf{B} (X = N), and from 3-amino-1,2,4-triazole (IIIa), four isomers **A–D** (X = CH) could be obtained. These structures cannot be distinguished on the basis of the ¹H and ¹⁹F NMR and IR spectra. Isotopically labeled compounds are widely used in the determination of molecular structure [10]. We have synthesized [¹⁵N]-labeled triazolopyrimidine VIa* from 3-oxo ester Ia, benzaldehyde, and 1-[¹⁵N]-3-amino-1,2,4-triazole (**IIIa***) (15 N concentration ~43%). In the 1 H NMR spectrum of compound VIa*, the 2-H signal appeared as a doublet at δ^{1} 7.78 ppm, $J({}^{1}\text{H}-{}^{15}\text{N}) = 15.3$ Hz, indicating the presence of ¹⁵N isotope. The intensity ratio of the 2-H resonance signals corresponding to the labeled (doublet) and unlabeled (singlet) molecules was consistent with the initial 15 N concentration (~ 43%) in triazolopyrimidine VIa*. The structure of VIa* was

established by ¹³C NMR spectroscopy. The C⁷ signal appeared in the spectrum as a doublet at $\delta_{\rm C}$ 60.06 ppm due to coupling with ¹⁵N, ²*J*(¹³C–¹⁵N) = 4.9 Hz, which can occur only in the [1,5-*a*]-fused isomer (**A**). Comparison of the ¹⁹F and ¹³C NMR data for **VIa**, **VIb**, and **VIIa** led us to conclude that these compounds also have structure **A**.

Tetrahydrotri- and -tetrazolo[1,5-*a*]pyrimidines **IVa–IVc** and **V** possess three asymmetric carbon atoms; therefore, four diastereoisomers (and, in addition, four respective enantiomers) are possible. According to the NMR data, compounds **IVa** and **IVb** having aryl substituents on C⁷ exist as a single diastereoisomer. Taking into account high conformational energies of the phenyl [ΔG (Ph) = 12.1 kJ/mol] and ethoxycarbonyl groups [ΔG (COOEt) = 5.3 kJ/mol], the most favorable conformation is that in which the above groups occupy equatorial positions [11]. This also follows from the coupling constant $J_{6,7} = 11.3-11.8$ Hz, which corresponds to axial orientation of the 6-H and 7-H protons [12]. The conformational energies of CF₃



 $[\Delta G(CF_3) = 8.8 \text{ kJ/mol}]$ and OH groups $[\Delta G(OH) = 2.2 \text{ kJ/mol}]$ in substituted cyclohexanones [11] suggest preferential equatorial orientation of the trifluoromethyl group. Moreover, in keeping with the X-ray diffraction data, just the same arrangement of the trifluoromethyl and hydroxy groups is typical of ethyl 2-oxo-4-phenyl-6-trifluoromethyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate [4] and dimethyl 2,6-di-hydroxy-2,6-bis(1,1,2,2-tetrafluoroethyl)-4-phenyl-tetrahydropyran-3,5-dicarboxylate [13].

The ¹H and ¹⁹F NMR spectra of 7-methyl-substituted tetrahydroazolo[1,5-a]pyrimidines IVc and V contained a double set of signals, indicating that they exist in solution (DMSO- d_6) as two diastereoisomers E and E' [ratio 3:2 (IVc) and 9:1 (V)]. The 6-H and 7-H signals of the major diastereoisomer (E) appear in the ¹H NMR spectra of **IVc** and **V** as doublets with J = 11.3 Hz, corresponding to diaxial orientation of these protons. Analogous signals from the minor diastereoisomer (E') are also split into doublets but with a smaller coupling constant, J = 4.5-4.6 Hz, which indicates than one proton is equatorial while the other is axial [12]. In addition, the 6-H proton in isomers E' is coupled with the OH proton through four bonds $({}^{4}J = 1.2 - 1.3$ Hz, W-coupling). This means that the ethoxycarbonyl group in E' occupies axial position and that the neighboring 6-H proton is equatorial. Comparison of the conformational energies of the ethoxycarbonyl and methyl groups $[\Delta G(Me) = 7.1 \text{ kJ/mol}]$ also suggests preferential change of orientation of the carbonyl-containing substituent [11].

Thus our results showed that the cyclocondensation of fluorinated 3-oxo esters **I** and aldehydes (or 2-benzylidene-2-fluoroacyl esters **II**) with aminoazoles **IIIa** and **IIIb** is regioselective and that the resulting bicyclic compounds belong to a single heterocyclic system.

EXPERIMENTAL

The IR spectra were recorded in the range from 400 to 4000 cm⁻¹ on a Perkin–Elmer Spectrum-1 Fourier spectrometer from samples dispersed in mineral oil. The ¹H NMR spectra were measured on a Bruker DRX-400 spectrometer at 400 MHz. The ¹⁹F NMR spectra were obtained on Tesla BS-587A (75.3 MHz) and Bruker DRX-400 (376 MHz) instruments using C_6F_6 as reference. The ¹³C NMR spectra were run on a Bruker DRX-400 spectrometer (100 MHz, TMS). DMSO- d_6 was used as solvent. Elemental analysis was

performed on a Carlo Erba CHNS-O EA 1108 analyzer. The ¹³C NMR spectra of compounds **VIa***, **VIb**, and **VIIa** are given in table.

2-Benzylidene-2-fluoroacyl esters **IIa** and **IIb** were synthesized by the procedures reported in [13, 14], and labeled $1-[^{15}N]$ -3-amino-1,2,4-triazole was prepared as described in [10].


Azolo[1,5-a]pyrimidines IV–VII (general procedure). a. A mixture of 0.01 mol of 3-oxo ester I, 0.01 mol of benzaldehyde, p-methoxybenzaldehyde, or acetaldehyde, and 0.01 mol of 3-amino-1,2,4-triazole or 5-aminotetrazole in 20 ml of ethanol containing a catalytic amount of hydrochloric acid was heated for 12 h under reflux. The mixture was evaporated, and the precipitate was washed with hot water and recrystallized from ethanol.

b. A mixture of 0.01 mol of 2-benzylidene-3-oxo ester **II** and 0.01 mol of 3-amino-1,2,4-triazole, 5-aminotetrazole, or $1-[^{15}N]$ -3-amino-1,2,4-triazole (43% of ^{15}N) in 10 ml of DMF was stirred for 12–14 h at 70°C. The mixture was poured into cold water, and the precipitate was filtered off, washed with hot water, and recrystallized from ethanol.


c. p-Toluenesulfonic acid, 0.05 g, was added to a solution of 0.01 mol of azolopyrimidine **IVa** or **IVb** in 100 ml of benzene, and the mixture was heated for 8 h with simultaneous removal of water as azeotrope with benzene. The solution was filtered while hot, the filtrate was evaporated, and the precipitate was recrystallized from ethanol.


Ethyl 5-hydroxy-7-phenyl-5-trifluoromethyl-4,5,6,7-tetrahydrotetrazolo[1,5-*a*]pyrimidine-6-carboxylate (IVa). Yield (*a*) 1.68 g (47%), mp 201– 202°C. IR spectrum, v, cm⁻¹: 3455, 3174 (NH, OH); 1720 (C=O); 1624, 1551 (C=C, C=N); 1080–1204 (C–F). ¹H NMR spectrum, δ, ppm: 0.87 t (3H, OCH₂CH₃, J = 7.1 Hz), 3.57 d (1H, 6-H, J = 11.8 Hz), 3.88 d.q and 3.86 d.q (1H each, OCH₂CH₃, J = 10.8, 7.1 Hz), 5.63 d (1H, 7-H, J = 11.8 Hz), 7.40–7.47 m (5H, C₆H₅), 7.99 s (1H, NH), 9.57 s (1H, OH). ¹⁹F NMR spectrum, δ_F, ppm: 82.71 s (CF₃). Found, %: C 46.89; H 3.93; F 15.97; N 19.50. C₁₄H₁₄F₃N₅O₃. Calculated, %: C 47.07; H 3.95; F 15.95; N 19.60.

Ethyl 5-hydroxy-7-(4-methoxyphenyl)-5-trifluoromethyl-4,5,6,7-tetrahydrotetrazolo[1,5-*a*]pyrimidine-6-carboxylate (IVb). Yield (*a*) 2.05 g (53%), mp 179–180°C. IR spectrum, v, cm⁻¹: 3451, 3175 (NH, OH); 1713 (C=O); 1613, 1518 (C=C, C=N); 1152–1206 (C–F). ¹H NMR spectrum, δ, ppm: ¹³C NMR spectra of azolo[1,5-*a*]pyrimidines VIa*, VIb, and VIIa in DMSO-*d*₆



Vla'





Atom	Chemical shifts δ_C , ppm		
	VIa*	VIb	VIIa
C^2	150.17 br.s	150.44 br.s	_
C^{3a}	146.62 br.s	146.65	148.40 br.s
C^5	131.18 br.q (J_{CF} = 34.2 Hz)	133.96 br.t ($J_{\rm CF}$ = 28.0 Hz)	130.14 br.q ($J_{\rm CF}$ = 36.3 Hz)
C ⁶	104.42	103.86	105.90 q ($J_{\rm CF}$ = 2.5 Hz)
C^7	$60.06 (J_{\rm CH} = 4.9 \text{ Hz})$	59.90	61.32
C^8	162.98	164.11	162.51 br.s
C ⁹	60.93	52.15	59.54
C^{10}	13.36	112.76 t.t ($J_{\rm CF}$ = 255.7, 27.6 Hz)	13.32
C ¹¹	119.94 q ($J_{\rm CF}$ = 276.1 Hz)	109.64 t.t ($J_{\rm CF}$ = 251.4, 30.2 Hz)	119.76 q ($J_{\rm CF}$ = 276.1 Hz)
C^i	139.33	139.75	137.93
C^o	127.22	126.90	127.70
\mathbf{C}^m	128.66	128.76	129.31
\mathbf{C}^p	128.66	128.63	128.97

0.90 t (3H, OCH₂CH₃, J = 7.1 Hz), 3.57 d (1H, 6-H, J = 11.8 Hz), 3.74 s (3H, OCH₃), 3.89 q (2H, OCH₂CH₃, J = 7.1 Hz), 5.58 d (1H, 7-H, J = 11.8 Hz), 6.93–6.97 m (4H, C₆H₄), 7.97 s (1H, NH), 9.54 s (1H, OH). ¹⁹F NMR spectrum, δ_F , ppm: 82.71 s (CF₃). Found, %: C 46.45; H 4.17; F 14.69; N 18.12. C₁₅H₁₆F₃N₅O₄. Calculated, %: C 46.52; H 4.16; F 14.72; N 18.08.

Ethyl 5-hydroxy-7-methyl-5-trifluoromethyl-4,5,6,7-tetrahydrotetrazolo[1,5-*a*]pyrimidine-6-carboxylate (IVc). Yield (*a*) 1.26 g (43%), mp 156– 158°C. IR spectrum, v, cm⁻¹: 3225, 3193 (NH, OH); 1740 (C=O); 1617, 1539 (C=C, C=N); 1087–1206 (C–F). ¹H NMR spectrum, δ, ppm (mixture of stereoisomers **E** and **E'**, 3:2): **E**: 1.21 t (3H, OCH₂CH₃, J =7.1 Hz), 1.61 d (3H, CH₃, J = 6.3 Hz), 3.20 d (1H, 6-H, J = 11.3 Hz), 4.18 q (2H, OCH₂CH₃, J = 7.1 Hz), 4.63 d.q (1H, 7-H, J = 11.3, 6.3 Hz), 7.79 s (1H, NH), 9.38 s (1H, OH); **E'**: 1.07 t (3H, OCH₂CH₃, J = 7.1 Hz), 1.61 d (3H, CH₃, J = 6.3 Hz), 3.30 d.d (1H, 6-H, J = 4.5, 1.3 Hz), 4.03 q (2H, OCH₂CH₃, J = 7.1 Hz), 4.39 d.q (1H, 7-H, J = 6.3, 4.5 Hz), 7.59 s (1H, NH), 8.80 br.d (1H, OH, J = 1.3 Hz). ¹⁹F NMR spectrum, $\delta_{\rm F}$, ppm (mixture of stereoisomers **E** and **E'**, 3:2): **E**: 82.51 s (CF₃); **E'**: 82.49 s (CF₃). Found, %: C 36.65; H 4.12; F 19.28; N 23.70. C₉H₁₂F₃N₅O₃. Calculated, %: C 36.62; H 4.10; F 19.31; N 23.72.

Ethyl 5-hydroxy-7-methyl-5-trifluoromethyl-4,5,6,7-tetrahydro[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxylate (V). Yield (*a*) 2.00 g (68%), mp 183– 185°C. IR spectrum, v, cm⁻¹: 3221, 3130, 3103 (NH, OH); 1746 (C=O); 1621, 1557 (C=N); 1096–1195 (C–F). ¹H NMR spectrum, δ, ppm (mixture of stereoisomers **E** and **E**', 9:1): **E**: 1.20 t (3H, OCH₂CH₃, J =7.1 Hz), 1.46 d (3H, CH₃, J = 6.4 Hz), 3.01 d (1H, 6-H, J = 11.3 Hz), 4.16 q (2H, OCH₂CH₃, J = 7.1 Hz), 4.39 d.q (1H, 7-H, J = 11.3, 6.4 Hz), 7.55 s (1H, NH), 7.56 s (1H, 2-H), 8.69 s (1H, OH); **E**': 1.05 t (3H, OCH₂CH₃, J = 7.1 Hz), 1.44 d (3H, CH₃, J = 6.4 Hz), 3.17 d.d (1H, 6-H, J = 4.6, 1.2 Hz), 4.02 q (2H, OCH₂CH₃, J = 7.1 Hz), 4.39 d.q (1H, 7-H, J = 6.4, 4.6 Hz), 7.50 s (1H, 2-H), 7.59 s (1H, NH), 8.80 br.d (1H, OH, J = 1.2 Hz). ¹⁹F NMR spectrum, δ_F , ppm (mixture of stereoisomers **E** and **E'**, 9:1): **E**: 82.33 s (CF₃); **E'**: 82.29 s (CF₃). Found, %: C 40.89; H 4.38; F 19.38; N 19.13. C₁₀H₁₃F₃N₄O₃. Calculated, %: C 40.82; H 4.45; F 19.37;N 19.04.

Ethyl 7-phenyl-5-trifluoromethyl-4,7-dihydro-[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxylate (VIa). Yield (*a*) 1.86 g (55%), (*b*) 2.33 g (69%); mp 157–159°C. IR spectrum, v, cm⁻¹: 3200 (NH); 1710 (C=O); 1600, 1559 (C=C, C=N); 1100–1200 (C–F). ¹H NMR spectrum, δ, ppm: 1.08 t (3H, OCH₂CH₃, J = 7.1 Hz), 4.01 q (2H, OCH₂CH₃, J =7.1 Hz), 6.36 q (1H, 7-H, $J_{HF} = 1.4$ Hz), 7.22–7.36 m (5H, C₆H₅), 7.61 s (1H, 2-H), 11.44 br.s (1H, NH). ¹⁹F NMR spectrum, δ_F, ppm: 99.64 d (CF₃, $J_{FH} =$ 1.4 Hz). Found, %: C 53.19; H 3.79; F 16.81; N 16.66. C₁₅H₁₃F₃N₄O₂. Calculated, %: C 53.26; H 3.87; F 16.84; N 16.56.

Ethyl 7-phenyl-5-trifluoromethyl-4,7-dihydro-[1-¹⁵N][1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxylate (VIa*). Yield (*b*) 2.03 g (60%), mp 155– 157°C. IR spectrum, v, cm⁻¹: 3203 (NH); 1711 (C=O); 1600, 1558 (C=C, C=N); 1100–1200 (C–F). ¹H NMR spectrum, δ, ppm: 1.01 t (3H, OCH₂CH₃, *J* = 7.1 Hz), 3.99 q (2H, OCH₂CH₃, *J* = 7.1 Hz), 6.43 q (1H, 7-H, *J*_{HF} = 1.4 Hz), 7.23–7.76 m (4H, C₆H₅), 7.78 d [1H, 2-H, $J(^{1}H-^{15}N) = 15.3$ Hz], 11.65 b.s (1H, NH).

Methyl 7-phenyl-5-(1,1,2,2-tetrafluoroethyl)-4,7dihydro[1,2,4]triazolo[1,5-a]pyrimidine-6-car**boxylate** (VIb). Yield (a) 1.60 g (45%), (b) 2.24 g (63%); mp 197–199°C. IR spectrum, v, cm⁻¹: 3462, 1624 (NH); 1712 (C=O); 1580, 1570, 1545 (C=C, C=N); 1115–1205 (C–F). ¹H NMR spectrum, δ, ppm: 3.58 s (3H, OCH₃), 6.39 t (1H, 7-H, $J_{\text{HF}} = 1.4$ Hz), 6.87 d.d.d.d [1H, $H(CF_2)_2$, $J_{HF} = 53.0$, 53.5, 6.7, 5.0 Hz], 7.21–7.36 m (5H, C₆H₅), 7.61 s (1H, 2-H), 11.45 br.s (1H, NH). ¹⁹F NMR spectrum, $\delta_{\rm F}$, ppm: 25.69 m (2F, HCF₂, AB system, $\Delta_{AB} = 0.26$ ppm, $J_{AB} =$ 300.0, $J_{\rm FH} = 53.0, 53.5, 6.7, 5.0$ Hz), 44.21 br.d (1F, CF_2 , $J_{FF} = 263.0$ Hz), 47.35 br.d (1F, CF_2 , $J_{FF} =$ 263.0 Hz). Found, %: C 50.28; H 3.39; F 20.98; N 15.79. $C_{15}H_{12}F_4N_4O_2$. Calculated, %: C 50.57; H 3.36; F 21.32; N 15.73.

Ethyl 7-phenyl-5-trifluoromethyl-4,7-dihydrotetrazolo[1,5-*a*]pyrimidine-6-carboxylate (VIIa). Yield (*a*) 1.69 g (50%), (*b*) 2.47 g (73%), (*c*) 3.29 g (97%); mp 194–196°C. IR spectrum, v, cm⁻¹: 3462, 3173 (NH); 1712 (C=O); 1624, 1549 (C=C, C=N); 1070–1235 (C–F). ¹H NMR spectrum, δ, ppm: 0.99 t (3H, OCH₂CH₃, J = 7.1 Hz), 4.00 q (2H, OCH₂CH₃, J = 7.1 Hz), 6.82 q (1H, 7-H, $J_{HF} = 1.5$ Hz), 7.36– 7.44 m (5H, C₆H₅), 12.01 br.s (1H, NH). ¹⁹F NMR spectrum, δ_F , ppm: 100.49 d (CF₃, $J_{FH} = 1.5$ Hz). Found, %: C 49.63; H 3.72; F 16.68; N 20.81. C₁₄H₁₂F₃N₅O₂. Calculated, %: C 49.57; H 3.57; F 16.79; N 20.64.

Methyl 7-phenyl-5-(1,1,2,2-tetrafluoroethyl)-4,7dihydrotetrazolo[1,5-*a*]pyrimidine-6-carboxylate (VIIb). Yield (*a*) 1.75 g (49%), (*b*) 2.00 g (56%), (*c*) 3.50 g (98%); mp 185–186°C. IR spectrum, v, cm⁻¹: 3430, 1590 (NH); 1720 (C=O); 1590, 1540 (C=C, C=N); 1060–1200 (C–F). ¹H NMR spectrum, δ, ppm: 3.57 s (3H, CH₃), 6.77 s (1H, 7-H), 6.87 t.d.d [1H, H(CF₂)₂, $J_{HF} = 53$, 7.4, 4.0 Hz], 7.29–7.41 m (5H, C₆H₅), 11.84 br.s (1H, NH). ¹⁹F NMR spectrum, δ_F , ppm: 26.05 d.t (2F, HCF₂, $J_{FH} = 53$, $J_{FF} = 8.7$ Hz), 46.04 m (2F, CF₂, *AB* system, $\Delta_{AB} = 4.15$ ppm, $J_{AB} =$ 267.5, $J_{FF} = 8.7$, $J_{FH} = 7.4$ Hz). Found, %: C 46.88; H 3.16; F 20.97; N 19.37. C₁₄H₁₁F₄N₅O₂. Calculated, %: C 47.07; H 3.10; F 21.27; N 19.60.

Ethyl 7-(4-methoxyphenyl)-5-trifluoromethyl-4,7-dihydrotetrazolo[1,5-*a*]pyrimidine-6-carboxylate (VIIc). Yield (*a*) 1.47 g (40%), mp 184– 186°C. IR spectrum, *v*, cm⁻¹: 3452 (NH); 1718 (C=O); 1615, 1518 (C=C, C=N); 1080–1206 (C–F). ¹H NMR spectrum, δ, ppm: 1.02 t (3H, OCH₂CH₃, *J* = 7.1 Hz), 3.77 s (3H, OCH₃), 4.00 q (2H, OCH₂CH₃, *J* = 7.1 Hz), 6.75 q (1H, 7-H, J_{HF} = 1.5 Hz), 7.25–7.41 m (4H, C₆H₄), 11.94 br.s (1H, NH). ¹⁹F NMR spectrum, δ_F, ppm: 100.48 d (CF₃, J_{FH} = 1.5 Hz). Found, %: C 48.72; H 3.80; F 15.39; N 18.98. C₁₄H₁₂F₃N₅O₂. Calculated, %: C 48.78; H 3.82; F 15.43; N 18.96.

This study was performed under financial support by the Russian Foundation for Basic Research (project nos. 03-03-33118 and 03-03-06472) and by the Program for State Support of Leading Scientific Schools (project no. 1766.2003.3).

REFERENCES

- 1. Mashkovskiii, M.D., *Lekarstvennye sredstva* (Drugs), Moscow: Novaya Volna, 2002, vol. 1, p. 413.
- 2. Kappe, C.O., Tetrahedron, 1993, vol. 49, p. 6937.
- Etwal, K.S., Rovnyak, G.C., O'Reilly, B.C., Gougoutas, J.Z., and Malley, M.F., *Heterocycles*, 1987, vol. 26, p. 1189.
- 4. Kappe, C.O., Falsone, S.F., Fabian, W.M.F., and Belay, F., *Heterocycles*, 1999, vol. 51, p. 77.
- 5. Saloutin, V.I., Burgart, Ya.V., Kuzueva, O.G., Kappe, C.O., and Chupakhin, O.N., *J. Fluorine Chem.*, 2000, vol. 103, p. 17.
- JPN Patent no. 61-227584; Chem. Abstr., 1987, vol. 106, no. 176416m.

- 7. EU Patent no. 328700; *Chem. Abstr.*, 1990, vol. 113, no. 29258c.
- 8. US Patent no. 918074; Chem. Abstr., 1991, vol. 114, no. 81873 j.
- Fedorova, O.V., Zhidovinova, M.S., Rusinov, G.L., and Ovchinnikova, I.G., *Izv. Ross. Akad. Nauk, Ser. Khim.*, 2003, p. 1677.
- Chupakhin, O.N., Ulomskii, E.N., Deev, S.L., Voronin, V.V., Kodess, M.I., and Rusinov, V.L., *Dostizheniya* v organicheskom sinteze. Sbornik statei (Advances in Organic Synthesis. A collection of Papers), Yekaterinburg: Ural. Otd. Ross. Akad. Nauk, 2003, p. 227.
- 11. Potapov, V.M., *Stereokhimiya* (Stereochemistry), Moscow: Khimiya, 1988, p. 211.
- Ionin, B.I., Ershov, B.A., and Kol'tsov, A.I., YaMRspektroskopiya v organicheskoi khimii (NMR Spectroscopy in Organic Chemistry), Leningrad: Khimiya, 1983, p. 154.
- Pryadeina, M.V., Kuzueva, O.G., Burgart, Ya.V., Saloutin, V.I., Lyssenko, K.A., and Antipin, M.Yu., *J. Fluorine Chem.*, 2002, vol. 117, p. 1.
- Pryadeina, M.V., Kuzueva, O.G., Burgart, Ya.V., and Saloutin, V.I., *Russ. J. Org. Chem.*, 2002, vol. 38, p. 224.